Stromedix, Inc. Awarded Grant Under the Qualifying Therapeutic Discovery Project Program
Stromedix received a grant in support of STX-100, a humanized monoclonal antibody to integrin avß6, in development for fibrotic diseases such as idiopathic pulmonary fibrosis and chronic allograft dysfunction in kidney transplant patients.
About Stromedix
Stromedix is a privately held biotechnology company based in Cambridge, Massachusetts, focused on innovative therapies for fibrotic organ failure. Investors in Stromedix include Atlas Venture, New Leaf Venture Partners, Frazier Healthcare Ventures, Bessemer Venture Partners and Red Abbey Venture Partners. Biogen Idec is also a shareholder. For more information on Stromedix, please visit http://www.stromedix.com.
CONTACT
Stromedix: Michael Gilman, Ph.D., (617) 674 8402 Chief Executive Officer michael.gilman@stromedix.com
Paul Kidwell 617.296.3854: Office 617.680.1088: Mobile